These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15479686)

  • 1. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
    van Deventer SJ; Tami JA; Wedel MK
    Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
    Miner PB; Wedel MK; Xia S; Baker BF
    Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
    van Deventer SJ; Wedel MK; Baker BF; Xia S; Chuang E; Miner PB
    Aliment Pharmacol Ther; 2006 May; 23(10):1415-25. PubMed ID: 16669956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
    Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK
    Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.
    Vegter S; Tolley K; Wilson Waterworth T; Jones H; Jones S; Jewell D
    Aliment Pharmacol Ther; 2013 Aug; 38(3):284-93. PubMed ID: 23750909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
    Miner P; Wedel M; Bane B; Bradley J
    Aliment Pharmacol Ther; 2004 Feb; 19(3):281-6. PubMed ID: 14984374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT; Sitaraman S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: alicaforsen (Isis).
    Gewirtz AT; Sitaraman SV
    Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
    Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
    Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
    J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.
    Greuter T; Vavricka SR; Biedermann L; Pilz J; Borovicka J; Seibold F; Sauter B; Rogler G
    Dig Dis; 2018; 36(2):123-129. PubMed ID: 29207381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
    Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
    Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
    Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
    Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.
    Safdi M; DeMicco M; Sninsky C; Banks P; Wruble L; Deren J; Koval G; Nichols T; Targan S; Fleishman C; Wiita B
    Am J Gastroenterol; 1997 Oct; 92(10):1867-71. PubMed ID: 9382054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alicaforsen for the treatment of inflammatory bowel disease.
    Jairath V; Khanna R; Feagan BG
    Expert Opin Investig Drugs; 2017 Aug; 26(8):991-997. PubMed ID: 28670932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.